Skip to main content

Lakefront Biotherapeutics NV

GLPGF
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0001421876

No open-market purchases or sales by Lakefront Biotherapeutics NV insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q3 2026; no superinvestor holds it.

Other share classesLKFT

Currency
EUR
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Oct 8, 2026, 1:06 PM ET

Amounts are in EUR, the currency Lakefront Biotherapeutics NV reports in. Lines marked ≈ US$ convert key figures to US dollars.

Revenue flow, FY2025

Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.

Income statement

Each column is one fiscal year, newest first.

Income statement of Lakefront Biotherapeutics NV, annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing20-F20-F20-F20-F20-F
Reported–––––
RevenueEUR 1.11B≈ US$1.26BEUR 275.6M≈ US$298.3MEUR 239.7M≈ US$259.3MEUR 505.3M≈ US$532.3MEUR 484.8M≈ US$573.6M
Cost of revenueEUR 29.7MEUR 34.9M–EUR 12.1MEUR 1.63M
Research and developmentEUR 459.4MEUR 335.5MEUR 241.3MEUR 515.1MEUR 491.7M
Selling, general and administrativeEUR 147.3MEUR 117.2MEUR 128.3MEUR 144.9MEUR 140.9M
Operating incomeEUR 295.0MEUR -188.3MEUR -88.3MEUR -267.5MEUR -165.6M
Interest expenseEUR 1.03MEUR 911.0KEUR 1.77MEUR 6.97MEUR 11.7M
Income taxEUR -18.6MEUR -1.80MEUR 9.61MEUR 2.84MEUR 2.42M
Net incomeEUR 320.9M≈ US$362.8MEUR 74.1M≈ US$80.2MEUR 211.7M≈ US$229.0MEUR -218.0M≈ US-$229.6MEUR -103.2M≈ US-$122.1M
EPS, basicEUR 4.87EUR 1.12EUR 3.21EUR -3.32EUR -1.58
EPS, dilutedEUR 4.87EUR 1.12EUR 3.21EUR -3.32EUR -1.58
Weighted shares, basic65.9M65.9M65.9M65.7M65.5M
Weighted shares, diluted65.9M65.9M–––
Margins and growth
Operating margin26.5%-68.3%-36.8%-52.9%-34.2%
Net margin28.9%26.9%88.3%-43.1%-21.3%
Revenue growth, year over year+303.5%+15.0%−52.6%+4.2%+1.4%
Net income growth, year over year+333.1%−65.0%–––

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of Lakefront Biotherapeutics NV, annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing20-F20-F20-F20-F20-F
Reported–––––
Cash and equivalentsEUR 87.9MEUR 64.2MEUR 166.8MEUR 508.1MEUR 2.23B
Accounts receivableEUR 9.57MEUR 32.5MEUR 17.5MEUR 28.2MEUR 91.8M
InventoryEUR 22.5MEUR 51.2MEUR 74.0MEUR 52.9MEUR 20.6M
Total current assetsEUR 3.08BEUR 3.34BEUR 3.86BEUR 4.24BEUR 4.86B
Property, plant and equipmentEUR 71.9MEUR 105.4MEUR 111.2MEUR 126.7MEUR 105.7M
Goodwill–EUR 70.0MEUR 69.6MEUR 69.8M–
Intangible assetsEUR 848.0KEUR 164.9MEUR 127.9MEUR 146.4MEUR 60.1M
Total assetsEUR 3.41B≈ US$4.00BEUR 4.14B≈ US$4.28BEUR 4.36B≈ US$4.82BEUR 4.73B≈ US$5.06BEUR 5.19B≈ US$5.88B
Accounts payableEUR 104.6MEUR 98.9MEUR 135.2MEUR 148.7MEUR 137.4M
Total current liabilitiesEUR 152.9MEUR 335.1MEUR 428.2MEUR 522.5MEUR 566.5M
Total liabilitiesEUR 170.7MEUR 1.24BEUR 1.56BEUR 2.21BEUR 2.55B
Shareholders' equityEUR 3.24BEUR 2.90BEUR 2.80BEUR 2.53BEUR 2.64B

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of Lakefront Biotherapeutics NV, annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing20-F20-F20-F20-F20-F
Reported–––––
Operating cash flowEUR -257.5M≈ US-$291.1MEUR -320.0M≈ US-$346.3MEUR -406.0M≈ US-$439.1MEUR -500.5M≈ US-$527.3MEUR -503.8M≈ US-$596.0M
Capital expendituresEUR 13.7MEUR 16.7MEUR 18.7MEUR 27.4MEUR 54.2M
Free cash flowEUR -271.2M≈ US-$306.6MEUR -336.7M≈ US-$364.4MEUR -424.7M≈ US-$459.4MEUR -527.9M≈ US-$556.1MEUR -558.0M≈ US-$660.2M
Stock-based compensationEUR 24.0MEUR 19.9MEUR 56.7MEUR 88.5MEUR 70.7M
Investing cash flowEUR 288.8MEUR 220.6MEUR 71.2MEUR -1.25BEUR 541.2M
Financing cash flowEUR -3.27MEUR -4.92MEUR -5.00MEUR -1.49MEUR -3.88M
Ratio
Stock-based compensation, % of revenue2.2%7.2%23.7%17.5%14.6%

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for Lakefront Biotherapeutics NV by cover date
Cover dateShares outstandingChange in a yearFiling
Dec 31, 202565.9M0.0%SEC
Dec 31, 202465.9M0.0%SEC
Dec 31, 202365.9M+0.1%SEC
Dec 31, 202265.8M+0.4%SEC
Dec 31, 202165.6M+0.2%SEC
Dec 31, 202065.4M+1.2%SEC
Dec 31, 201964.7M+18.7%SEC
Dec 31, 201854.5M+6.9%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
  • ≈ US$ figures convert EUR at FRED H.10 exchange rates (Federal Reserve): the average rate over the period for income and cash flow, and the rate on the period-end date, or the last business day before it, for the balance sheet.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS. Their cover share count adds up the classes but only for the last few filings, so there can be a gap before them.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.